The overall aim of Liqbiopsens project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of ctDNA and their KRAS and BRAF mutations associated to colorectal cancer through blood samples.

The main features of Liqbiopsens are:

  • Reliability: Liqbiopsens platform is based on DestiNA Genomics DGL© technology with its unique detection of only correct sequences of nucleic acids. Using this method, detection rates vary from 95–100 % with false positive rates of 1–5 % depending on the screen performed, the cancer stage at the time it is performed.
  • Low-cost: Our preliminary commercial studies estimate a cost around 10000€ for the platform and a cost of between 40 and 50 € for each analysis of 27 KRAS and BRAF mutations, comprising a disposable test cartridge and the needed reagents kit.
  • Multiplexing Capacities: Liqbiopsens is able to use a single sample to genotype multiple mutations without the need of splitting the sample in as many portions as mutations, thus reducing importantly the number of errors. A volume sample of 2-5 ml will be enough to study up to 27 KRAS and BRAF mutations.
  • Sensitivity: Combination of a novel design of very high frequency acoustic wave microsensors, an automated micro-fluidic system, a isothermal pre-amplification stage and a novel high resolution measurement technique results in a very sensitive platform. Liqbiopsens proposal aims to get a limit of detection (LoD) in the zM range.
  • Short analysis time: Platform transduction method is based on acoustic wave microsensor technology that is a direct label-free transduction method. Acoustic techniques avoid the need of using costly and time-consuming sample labelling procedures. Furthermore, an optimized microfluidic system delivers sample in very small volumes, reducing interaction time needed to perform a measurement. An expected time of 30-60 min will be needed to complete the analysis.
  • User-friendly: Every step during the measurement procedure (including calibration) will be automated. The design of the control interface is user-driven to assure an optimized performance in real application environment. ‘One-button’ operation will not only provide a user-friendly experience but it will also ensure the repeatability of the measurements.
  • Flexibility: System operation is based on a miniaturized pluggable cartridge that contains an array of acoustic wave sensors able to be functionalized to detect different ctDNA mutations. This cartridge includes a microfluidic layer for sample pre-treating and delivering. Its format is environmentally friendly and it can be safely disposed. 


RSS de esta página
Advance Wave Sensors SL
Destina Genomics Ltd.
Foundation for Research & Technology - Hellas
Servicio Andaluz de Salud - Hospital Universitario San Cecilio Granada
Sistemas Genómicos SL
Université Catholique de Louvain - ICTEAM
Co-funded by the Horizon 2020 Framework Programme of the European Union